---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000576"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:14:40.256839+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics completes GLP-tox study for SAB-142 T1D therapeutic; IND filing within 12 months

## Summary
- SAB-142 well tolerated in GLP-tox study; dose-dependent pharmacologic effect confirmed.
- First fully-human anti-thymocyte hpAB for type 1 diabetes; may avoid immune reactions seen with animal-derived antibodies.
- SAB to submit IND filing within approximately 12 months.
- SAB-142 dosed at 1, 5, and 10 mg/kg; prolonged lymphodepletion suggests potential for optimized dosing.
- Potential to delay onset/progression of type 1 diabetes and other T-cell mediated autoimmune diseases.

## SEC filing metadata
- accession: 0000950170-23-000576
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/0000950170-23-000576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/sabs-20230110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000576
- JSON: https://secwatch.observer/filing/0000950170-23-000576.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.